Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases
暂无分享,去创建一个
C. Marosi | M. Preusser | S. Zöchbauer-Müller | M. A. Hoda | T. Klikovits | G. Widhalm | J. Frischer | B. Gatterbauer | A. Berghoff | K. Dieckmann | A. Grisold | A. Steindl | S. Yadavalli | K. Gruber | M. Seiwald | M. Hoda
[1] E. Cho,et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Tonn,et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion , 2018, ESMO Open.
[3] Ying Zhang,et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[4] Rafal Dziadziuszko,et al. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. , 2017 .
[5] W. Mason. NANO, a practical scale for neurologic assessments in patients with brain tumors? , 2017, Neuro-oncology.
[6] M. Weller,et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) , 2017, Neuro-oncology.
[7] Kiwon Lee,et al. Critical Care Management of Cerebral Edema in Brain Tumors , 2017, Journal of intensive care medicine.
[8] H. Groen,et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[9] A. Vortmeyer,et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[10] A. Bezjak,et al. The Brain Metastases Symptom Checklist as a novel tool for symptom measurement in patients with brain metastases undergoing whole-brain radiotherapy. , 2016, Current oncology.
[11] J. Hainfellner,et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers , 2016, ESMO Open.
[12] M. Taphoorn,et al. Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide , 2015, Journal of Neuro-Oncology.
[13] M. Mehta,et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria , 2014, Neuro-oncology.
[14] C. Vecht,et al. Seizure prognosis in brain tumors: new insights and evidence-based management. , 2014, The oncologist.
[15] E. Shaw,et al. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. , 2013, Neuro-oncology.
[16] M. Proescholdt,et al. Surgical Resection of Brain Metastases—Impact on Neurological Outcome , 2013, International journal of molecular sciences.
[17] D. Schadendorf,et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. , 2012, European journal of cancer.
[18] Daniela Prayer,et al. Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases , 2012, Clinical & Experimental Metastasis.
[19] J. Wolchok,et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[20] Xianghua Luo,et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Brown,et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. , 2009, International journal of radiation oncology, biology, physics.
[22] A. Jena,et al. Magnetic Resonance (MR) Patterns of Brain Metastasis in Lung Cancer Patients: Correlation of Imaging Findings with Symptom , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] Martin Klein,et al. Cognitive deficits in adult patients with brain tumours , 2004, The Lancet Neurology.
[24] Desmond Curran,et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Posner,et al. Headaches in patients with brain tumors , 1993, Neurology.
[26] M. Shoykhet,et al. Emergency Neurological Life Support: Intracranial Hypertension and Herniation , 2017, Neurocritical Care.
[27] H. Groen,et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.
[28] Wade S. Smith,et al. Emergency Neurological Life Support: Intracranial Hypertension and Herniation , 2012, Neurocritical Care.
[29] Roy A. Patcheil. Brain metastases. , 1991, Neurologic clinics.